Improvements in BILAG Musculoskeletal and Mucocutaneous Domains at Week 48 in a Phase 2 Double-Blind Placebo-Controlled Trial of ABBV-599 (Elsubrutinib + Upadacitinib Combination) and Upadacitinib Monotherapy for Treatment of Moderately to Severely Active Systemic Lupus Erythematosus
Bibliographic record
Abstract
Objectives ABBV-599 is a novel combination of elsubrutinib (ELS; a selective Bruton’s tyrosine kinase inhibitor) and upadacitinib (UPA; a selective Janus kinase inhibitor), which targets separate signaling pathways associated with SLE. After 48 weeks of treatment with ABBV-599 high dose (HD; ELS 60 mg + UPA 30 mg) or UPA 30 mg monotherapy in the phase 2 SLEek study, patients with SLE demonstrated improvements in composite disease activity measures (BICLA and SRI-4) and flares compared with placebo. The objective of this post hoc analysis of the SLEek trial was to evaluate changes from baseline at week 48 in BILAG domains in patients with SLE receiving ABBV-599 HD, UPA 30 mg, or placebo. Methods In this multicenter, double-blind trial ( NCT03978520 ), patients with moderately to severely active SLE were randomized 1:1:1:1:1 to receive once daily ABBV-599 HD, ABBV-599 low dose (LD; ELS 60 mg + UPA 15 mg), ELS 60 mg, UPA 30 mg, or placebo. After a planned interim analysis, the ABBV-599 LD and ELS 60 mg groups were discontinued for lack of efficacy. This post hoc analysis evaluated BILAG domains and improving score shifts from baseline to week 48 in the continued treatment groups. For this analysis, definitions of 1-score shifts were BILAG A to B or B to C, 2-score shifts were BILAG A to C or B to D, and 3-score shifts were BILAG A to D. Results Among patients with BILAG A or B domain activity at baseline, a higher proportion of the ABBV-599 HD or UPA 30 mg groups than placebo achieved improvements in the BILAG musculoskeletal and mucocutaneous domains at week 48 (Table). Among patients in the UPA 30 mg and ABBV-599 HD groups who achieved an improvement, 2- or 3-score shifts from baseline to week 48 were achieved by > 80% and > 50% of patients in the musculoskeletal and mucocutaneous domains, respectively. Conclusions could not be drawn regarding the remaining BILAG domains due to small sample sizes and exclusion of patients with active neuropsychiatric SLE or severely active lupus nephritis. Table. Proportions of Patients With Baseline BILAG A or BILAG B Domain Activity Who Achieved Improvement in BILAG Domains at Week 48 Conclusion Both the ABBV-599 HD and UPA 30 mg treatment groups showed improvements in the musculoskeletal and mucocutaneous BILAG domains at week 48 compared with placebo. This analysis allows an early comparison of these frequent individual manifestations in a smaller trial and highlights the importance of examining improvement in each. A large global phase 3 program to expand the evaluation of UPA in SLE is ongoing ( NCT05843643 ).
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.007 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".